The relationship between myeloid-derived supressor cells and clinico-laboratory parameters in patients with liver cyrrosis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the present study, we used multicolor flow cytometry assay to measure the numbers of various myeloid suppressor cell subpopulations (Lin-HLA-DR-CD33+, Lin-HLA-DR-CD33+CD66b+, and CD14+HLA-DRlow/-) in peripheral blood of 51 participants, including 33 patients with viral- and 1 8 patients with «nonviral» (alcoholic or biliary/autoimmune) liver cirrhosis. Patients in both groups had increased proportions of Lin-HLA-DR-CD33+, Lin-HLA-DR-CD33+CD66b+, and CD 14+HLA-DRlow/-cells which levels did not depend on the type and replication of the virus in viral liver cirrhosis. In viral liver cirrhosis, the relative numbers of Lin-HLA-DR-CD33+cells directly correlated with the albumin levels (Rs=0.45; p=0.029). In «nonviral» group an inverse relationship was found between these indicators (Rs = -0.56; p=0.02), in addition the proportion of Lin-HLA-DR-CD33+and CD14+HLA-DRlow/-cells directly correlated with disease severity scores (Child-Pugh and MELD) direct correlation of the proportion of Lin-HLA-DR-CD33+and CD14+HLA-DRlow/-cells with the disease severity scores (Child-Pugh and MELD). Comparison of the initial content of myeloid suppressors with the response to complex therapy (that included autologous bone marrow-derived cell transplantation), showed that in viral liver cirrhosis, the proportion of Lin-HLA-DR-CD33+cells was characterized by a prognostic significance and, at values <1.9%, allowed to predict a decrease in the Child-Pugh score at 12 month follow-up with a sensitivity of 83.3% and a specificity of 71.4%. The data obtained indicate the relationship between myeloid-derived suppressor cells and albumin levels, disease severity and response to therapy, suggesting myeloid suppressors as a new therapeutic target in the liver cirrhosis.

Full Text

Restricted Access

About the authors

O. Yu Leplina

Research Institute of Fundamental and Clinical Immunology»

Email: oleplina@mail.ru
Novosibirsk, Russia

M. A Tikhonova

Research Institute of Fundamental and Clinical Immunology»

Email: oleplina@mail.ru
Novosibirsk, Russia

T. V Tyrinova

Research Institute of Fundamental and Clinical Immunology»

Email: oleplina@mail.ru
Novosibirsk, Russia

I. V Meledina

Research Institute of Fundamental and Clinical Immunology»

Email: oleplina@mail.ru
Novosibirsk, Russia

O. I Zheltova

Research Institute of Fundamental and Clinical Immunology»

Email: oleplina@mail.ru
Novosibirsk, Russia

A. A Ostanin

Research Institute of Fundamental and Clinical Immunology»

Email: oleplina@mail.ru
Novosibirsk, Russia

E. R Chernykh

Research Institute of Fundamental and Clinical Immunology»

Email: oleplina@mail.ru
Novosibirsk, Russia

References

  1. Albillos A., Martin-Mateos R., Van der Merwe S. et al. Cirrhosis-associated immure dysfunction. Nat. Rev. Gastroenterol. Hepatol. 2021; 61(6): 1385-96.
  2. Gabrilovich D.I. Myeloid-derived suppressor cells. Cancer Immunol. Res. 2017; 5(1): 3-8.
  3. Rajabinejad M., Salari F., Karaji A.G. et al. The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells? Artif. Cells, Nanomed. Biotechnol. 2019; 47(1): 4149-58.
  4. Consonni F.M., Porta C., Marino A. et al. Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. Front. Immunol. 2019; 10: 949.
  5. Veglia F., Sanseviero E., Gabrilovich D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 2021; 21: 485-98.
  6. Sehgal R., Kaur N., Ramakrishna G. et al. Immune surveillance by Myeloid derived suppressor cells (MDSCs) in liver diseases. Dig. Dis. 2021; doi: 10.1159/000517459.
  7. Hammerich L., Tacke F. Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis. World J. Gastrointest. Pathophysiol. 2015; 6(3): 43-50.
  8. Zhou G.P., Jiang Y.Z., Sun L.Y. et al. Therapeutic effect and safety of stem cell therapy for chronic liver disease: a systematic review and metaanalysis of randomized controlled trials. Stem Cell Res. Ther. 2020; 11: 419.
  9. Shevela E.Y., Starostina N., Pal'tsev A. et al. Efficiency of Cell Therapy in Liver Cirrhosis. Bull. Exp. Biol. Med. 2016; 160(4): 542-7.
  10. Bernsmeier C., Triantafyllou E., Brenig R. et al. CD14+ CD15-HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure. Gut 2018; 67(6): 1155-67.
  11. Li H., Dai F., Peng Q. et al. Myeloid-derived suppressor cells suppress CD4+ and CD8+ T cell responses in autoimmune hepatitis. Mol. Med. Rep. 2015; 12(3): 3667-73.
  12. Longhi M.S., Ma Y., Vergani М. et al. Aetiopathogenesis of autoimmune hepatitis. J. Autoimmun. 2010; 34: 7-14.
  13. Kong X., Sun R., Chen Y. et al. yST cells drive myeloid-derived suppressor cell mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance. J. Immunol. 2014; 193(4): 1645-53.
  14. Zhang H., Lian M., Zhang J. et al. A functional characteristic of cysteine-rich protein 61: modulation of myeloid-derived suppressor cells in liver inflammation. Hepatology 2018; 67(1): 232-46.
  15. Zeng Q., Yang B., Sun H.Q. et al. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR Z chain expression on CD8 (+) T cells in chronic hepatitis C patients. Mol. Cells 2014; 37(1): 66.
  16. Suh Y.G., Kim J., Byun J. et al. CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology 2012; 56(5): 1902-12.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2021 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies